Last updated: April 2, 2026
What is the Drug with NDC 83107-0023?
NDC 83107-0023 corresponds to Xyrem (sodium oxybate), a central nervous system depressant used primarily to treat narcolepsy with cataplexy and certain cases of idiopathic hypersomnia. Xyrem is marketed by Jazz Pharmaceuticals. The drug is a Schedule III controlled substance in the U.S. due to its potential for abuse.
Market Size and Demand Dynamics
Prevalence and Patient Population
- Narcolepsy affects approximately 0.02-0.06% of the U.S. population, estimated between 70,000 to 210,000 individuals.
- Medication penetration: Approximately 70% of these patients are diagnosed, with about 50-60% actively receiving pharmacotherapy.
- Demand estimate: Based on prevalence, total market volume may approximate 35,000 to 125,000 prescriptions annually.
Competitive Landscape
- Primary competitors include Xyrem’s branded formulation, generic sodium oxybate options (limited due to scheduling), and alternative treatments like modafinil or sodium oxybate formulations with different dosing regimens.
- Market share: Xyrem maintains approximately 85% of the narcolepsy treatment market with proven efficacy and established safety profile.
Market Drivers
- Increased awareness and improved diagnosis rates.
- Off-label use for other sleep disorders and neuropsychiatric conditions.
- Evidence supporting efficacy in pediatric narcolepsy—expanding eligible patient base.
Regulatory and Reimbursement Environment
- Medicaid, Medicare, and private insurance fully reimburse Xyrem's costs with prior authorization.
- Strict schedule III classification limits distribution; specialty pharmacies manage dispensing.
Price Trends and Projections
Current Pricing Structure
| Metric |
Data |
| Average Wholesale Price (AWP) |
~$60 per 2.5 g dose (per night) |
| Average Wholesale Price (AWP) |
Approximately $300 per 30-dose supply |
| Typical retail price |
$450-$550 monthly |
| Reimbursement rate |
Generally aligns with AWP, varies by insurer |
Historical Price Trends (Last 5 Years)
- Stable pricing, with minor fluctuations (±10%) attributed to insurance negotiations and formulary positioning.
- Pricing increases have been generally driven by inflation, supply chain costs, and regulatory compliance expenses.
Future Price Projections (Next 3-5 Years)
- Projected price stability due to limited generic competition.
- Potential increases of 3-4% annually driven by inflation and retention of exclusivity.
- Risk of price erosion if regulations loosen or if generic sodium oxybate formulations become approved and accepted.
Impact of Regulatory Changes and Market Entry of Generics
- Regulatory climate: Any change in scheduling or approval of generics could cut prices by up to 50%, as seen with other controlled substances.
- Generic entry: Limited due to Schedule III classification, but recent legislative efforts could change this landscape in the future.
Price Sensitivity and Market Share
- Pricing is sensitive to insurance coverage and patient access programs.
- High efficacy and low side-effect profile sustain patient loyalty, maintaining pricing power.
Market Outlook Summary
- The proprietary nature of Xyrem constrains significant price erosion.
- The expanding diagnosis awareness and potential off-label uses support market growth.
- Price increases are unlikely to exceed 4%, barring regulatory or patent challenges.
Key Takeaways
- NDC 83107-0023 (Xyrem) operates in a niche market with stable demand and high brand loyalty.
- Market size remains limited by prevalence but benefits from increasing diagnosis.
- Pricing dynamics indicate stability with moderate increases expected annually.
- Competitive threats from generics are limited due to scheduling constraints but could emerge with regulatory changes.
- Future revenue depends on patient access, insurance reimbursement policies, and regulatory developments.
FAQs
1. How does the Schedule III classification affect market entry?
It limits distribution to specialty pharmacies and complicates generic development, contributing to price stability.
2. What factors could lead to a significant price drop?
Approval of generic sodium oxybate formulations or reclassification to a lower scheduling status.
3. Is there potential for new indications to expand the market?
Yes, off-label uses for other sleep and neuropsychiatric conditions are under investigation, potentially increasing demand.
4. How does insurance reimbursement influence pricing?
Reimbursement rates tend to follow AWP, and insurance formularies influence patient access and overall sales volume.
5. What impact could regulatory changes have on the market?
Loosening of scheduling or approval of generics could drastically decrease prices, impacting revenue and profit margins.
References
[1] IQVIA. (2022). Market Data on Sleep Disorder Medications.
[2] FDA. (2021). Schedule III Substance Regulations.
[3] Jazz Pharmaceuticals. (2023). Xyrem Prescribing Information.
[4] Medscape. (2022). Narcolepsy Treatment Landscape.
[5] Statista. (2023). U.S. Prescription Data for Narcolepsy Medications.
